查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1869809

皮膚癌診斷市場規模、佔有率和趨勢分析報告：按癌症類型、檢測類型、最終用途、地區和細分市場預測（2025-2033 年）

Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Melanoma, Non-Melanoma), By Test Type (Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests) By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

皮膚癌診斷市場摘要

2024年全球皮膚癌診斷市場規模估計為95.8億美元，預計2033年將達到156.7億美元。

預計從 2025 年到 2033 年，該行業將以 5.7% 的複合年成長率成長。人工智慧 (AI) 的整合、技術進步以及患者對非侵入性診斷方法的偏好是推動這一成長的主要因素。

此外，人們對皮膚癌的認知不斷提高、人工智慧診斷工具的進步、早期檢測的推廣以及發病率的上升（尤其是在日曬部位），預計都將推動市場成長。例如，根據美國癌症協會統計，侵襲性黑色素瘤僅佔所有皮膚癌病例的1%，預計2024年美國將新增約100,640例侵襲性黑色素瘤和99,700例原位黑色素瘤。醫療機構與科技公司之間的合作，透過提高診斷的可及性和準確性，進一步促進了這一成長。

此外，人工智慧驅動的產品核可等先進技術正在推動市場成長。例如，2024年1月，美國食品藥物管理局（FDA）核准了DermaSensor設備，這是首款由人工智慧驅動的皮膚癌診斷工具。 DermaSensor能夠對包括黑色素瘤、鱗狀細胞癌和基底細胞癌在內的多種皮膚癌進行定量、即時的識別。 DermaSensor設備也採用了人工智慧（AI）驅動的光譜技術來識別病變的細胞和亞細胞特徵。

現代機器學習技術依賴大型資料集來識別可用於分類的模式，這使得診斷成像成為人工智慧研究的一個極具前景的領域。此外，由於臨床和皮膚鏡影像的解讀具有主觀性，皮膚癌檢測對於人工智慧尤其具有吸引力。人工智慧輔助診斷還具有許多優勢，例如可以更便捷地獲得專家診療服務（這在許多地區往往是匱乏的），從而避免長時間的專家預約等待。人們越來越樂觀地認為，基於人工智慧的系統或許能夠提供比人類專家更高的診斷一致性和準確性。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 皮膚癌診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 皮膚癌診斷市場分析工具
    • 產業分析—波特五力分析
    • PESTEL 分析

第4章 皮膚癌診斷市場：按癌症類型分類的估計和趨勢分析

  • 全球皮膚癌診斷市場：癌症類型概覽
  • 全球皮膚癌診斷市場：依癌症類型分析變化
  • 全球皮膚癌診斷市場，按癌症類型和收入分類
  • 黑色素瘤
  • 非黑色素瘤

第5章：皮膚癌診斷市場：檢測類型估算與趨勢分析

  • 全球皮膚癌診斷市場：檢測類型概覽
  • 全球皮膚癌診斷市場：檢測類型差異分析
  • 全球皮膚癌診斷市場，按檢測類型和收入分類
  • 皮膚鏡檢查
  • 皮膚切片檢查
  • 淋巴結活體組織切片
  • 影像檢查
  • 其他

第6章：皮膚癌診斷市場：終端使用者需求預測及趨勢分析

  • 全球皮膚癌診斷市場：終端用戶儀表板
  • 全球皮膚癌診斷市場：終端用途差異分析
  • 全球皮膚癌診斷市場，按最終用途和收入分類
  • 醫院和診所
  • 研究所
  • 其他

7. 皮膚癌診斷市場：按癌症類型、檢測類型和最終用途分類的區域估算和趨勢分析

  • 區域儀錶板
  • 市場規模、預測趨勢分析（2021-2033）：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商和通路合作夥伴名單
    • 主要客戶
    • 主要企業市佔率分析（2024 年）
    • Castle Bioscience
    • DermTech
    • bioMerieux Inc.
    • FOUNDATION MEDICINE, INC.
    • DermaSensor, Inc.
    • F Hoffmann-La Roche Ltd
    • NeoGenomics Laboratories
    • Quest Diagnostics Incorporated
    • SkylineDx
    • Abbott
Product Code: GVR-4-68040-322-6

Skin Cancer Diagnostics Market Summary

The global skin cancer diagnostics market size was estimated at USD 9.58 billion in 2024 and is projected to reach USD 15.67 billion by 2033, growing at a CAGR of 5.7% from 2025 to 2033. The integration of artificial intelligence, technological advancements, and patient preference for non-invasive diagnostics drives the growth.

Furthermore, increased awareness about skin cancer, advancements in AI-based diagnostic tools, and initiatives promoting early detection, rising incidence, particularly in sun-exposed regions, are expected to drive the market growth. For instance, according to the American Cancer Society, invasive melanoma accounts for only 1% of all skin cancer cases, and in 2024, an estimated 100,640 new cases of invasive and 99,700 cases of in situ melanoma were diagnosed in the U.S. Partnerships between healthcare providers and tech companies further support this growth by enhancing accessibility and accuracy of diagnoses.

Furthermore, advanced technologies such as AI-enabled product approvals are driving the growth of the market. For instance, in January 2024, the FDA approved the first AI-powered skin cancer diagnostic tool, namely the DermaSensor device. Further, DermaSensor provides quantitative, point-of-testing identification for skin cancer, including melanoma, squamous cell carcinoma, and basal cell carcinoma. Also, the DermaSensor device uses artificial intelligence (AI)-powered spectroscopy in order to identify cellular and subcellular characteristics of lesions.

Modern machine learning techniques rely on extensive datasets to identify patterns useful for classification, with diagnostic imaging being a particularly promising area for AI research. Moreover, skin cancer detection, in particular, is an attractive test type for AI due to the subjective nature of clinical and dermoscopic image interpretation. Also, AI-assisted diagnosis offers advantages such as improved access to specialist expertise, which is often scarce in many regions, leading to long waiting times for specialist appointments. There is growing optimism that AI-based systems could offer greater consistency and higher accuracy than human experts.

Global Skin Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global skin cancer diagnostics market report based on cancer type, test type, end use, and region:

  • Cancer Type Outlook (Revenue, USD Million; 2021 - 2033)
  • Melanoma
  • Non-Melanoma
  • Test Type Outlook (Revenue, USD Million; 2021 - 2033)
  • Dermatoscopy
  • Skin Biopsy
  • Lymph node biopsy
  • Imaging Tests
  • Others
  • End Use Outlook (Revenue, USD Million; 2021 - 2033)
  • Hospital and Clinics
  • Laboratories
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Kuwait
    • UAE

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer Type
    • 1.2.2. Test Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Scope & Assessment
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer type and test type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Skin Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements
      • 3.2.1.2. Integration of artificial intelligence
      • 3.2.1.3. Patient preference for non-invasive diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Diagnostic Imaging
  • 3.3. Skin Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Skin Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis

  • 4.1. Global Skin Cancer Diagnostics Market: Cancer Type Dashboard
  • 4.2. Global Skin Cancer Diagnostics Market: Cancer Type Movement Analysis
  • 4.3. Global Skin Cancer Diagnostics Market by Cancer Type, Revenue
  • 4.4. Melanoma
    • 4.4.1. Melanoma market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Non-Melanoma
    • 4.5.1. Non-Melanoma market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Global Skin Cancer Diagnostics Market: Test Type Dashboard
  • 5.2. Global Skin Cancer Diagnostics Market: Test Type Movement Analysis
  • 5.3. Global Skin Cancer Diagnostics Market by Test Type, Revenue
  • 5.4. Dermatoscopy
    • 5.4.1. Dermatoscopy market estimates and forecasts for 2021 to 2033 (USD Million)
  • 5.5. Skin Biopsy
    • 5.5.1. Skin Biopsy market estimates and forecasts for 2021 to 2033 (USD Million)
  • 5.6. Lymph node biopsy
    • 5.6.1. Lymph node biopsy market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Imaging Tests
    • 5.7.1. Imaging Tests market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)

Chapter 6. Skin Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Global Skin Cancer Diagnostics Market: End Use Dashboard
  • 6.2. Global Skin Cancer Diagnostics Market: End Use Movement Analysis
  • 6.3. Global Skin Cancer Diagnostics Market by End Use, Revenue
  • 6.4. Hospital and Clinics
    • 6.4.1. Hospital and Clinics market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Laboratories
    • 6.5.1. Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Analysis market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Skin Cancer Diagnostics Market: Regional Estimates & Trend Analysis by Cancer Type, Test Type, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts for 2021 to 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Castle Bioscience
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. DermTech
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. bioMerieux Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. FOUNDATION MEDICINE, INC.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. DermaSensor, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. F Hoffmann-La Roche Ltd
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. NeoGenomics Laboratories
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Quest Diagnostics Incorporated
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. SkylineDx
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Abbott
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America skin cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 4 North America skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 5 North America skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 6 U.S. skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 7 U.S. skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 8 U.S. skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 9 Canada skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 10 Canada skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 11 Canada skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 12 Mexico skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 13 Mexico skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 14 Mexico skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Europe skin cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 17 Europe skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 18 Europe skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Germany skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 20 Germany skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 21 Germany skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 22 UK skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 23 UK skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 24 UK skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 25 France skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 26 France skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 27 France skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Italy skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 29 Italy skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 30 Italy skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 31 Spain skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 32 Spain skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 33 Spain skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Denmark skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 35 Denmark skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 36 Denmark skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Sweden skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 38 Sweden skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 39 Sweden skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 40 Norway skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 41 Norway skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 42 Norway skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific skin cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 47 China skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 48 China skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 49 China skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 50 Japan skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 51 Japan skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 52 Japan skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 53 India skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 54 India skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 55 India skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 56 South Korea skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 57 South Korea skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 58 South Korea skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Australia skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 60 Australia skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 61 Australia skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 62 Thailand skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 63 Thailand skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 64 Thailand skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Latin America skin cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 67 Latin America skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 68 Latin America skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 69 Brazil skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 70 Brazil skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 71 Brazil skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 72 Argentina skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 73 Argentina skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 74 Argentina skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 75 MEA skin cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 77 MEA skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 78 MEA skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 79 South Africa skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 80 South Africa skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 81 South Africa skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 85 UAE skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 86 UAE skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 87 UAE skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 88 Kuwait skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 89 Kuwait skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 90 Kuwait skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Skin cancer diagnostics market: market outlook
  • Fig. 14 Skin cancer diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Skin cancer diagnostics market driver impact
  • Fig. 18 Skin cancer diagnostics market restraint impact
  • Fig. 19 Skin cancer diagnostics market: Cancer Type movement analysis
  • Fig. 20 Skin cancer diagnostics market: Cancer Type outlook and key takeaways
  • Fig. 21 Melanoma market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Non-Melanoma estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Skin cancer diagnostics market: Test Type movement analysis
  • Fig. 24 Skin cancer diagnostics market: Test Type outlook and key takeaways
  • Fig. 25 Dermatoscopy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Skin biopsy estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Lymph node biopsy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Imaging tests market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Others estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Skin cancer diagnostics market: End use movement analysis
  • Fig. 31 Skin cancer diagnostics market: End use outlook and key takeaways
  • Fig. 32 Hospital and clinics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Laboratories estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Others estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Global skin cancer diagnostics market: Regional movement analysis
  • Fig. 36 Global skin cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 37 Global skin cancer diagnostics market share and leading players
  • Fig. 38 North America, by country
  • Fig. 39 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 U.S. key country dynamics
  • Fig. 41 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Canada key country dynamics
  • Fig. 43 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Mexico key country dynamics
  • Fig. 45 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 UK key country dynamics
  • Fig. 48 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Germany key country dynamics
  • Fig. 50 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 France key country dynamics
  • Fig. 52 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Italy key country dynamics
  • Fig. 54 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Spain key country dynamics
  • Fig. 56 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Denmark key country dynamics
  • Fig. 58 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Sweden key country dynamics
  • Fig. 60 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Norway key country dynamics
  • Fig. 62 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 China key country dynamics
  • Fig. 65 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Japan key country dynamics
  • Fig. 67 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 India key country dynamics
  • Fig. 69 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Thailand key country dynamics
  • Fig. 71 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 South Korea key country dynamics
  • Fig. 73 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Australia key country dynamics
  • Fig. 75 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Brazil key country dynamics
  • Fig. 78 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Argentina key country dynamics
  • Fig. 80 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 South Africa key country dynamics
  • Fig. 83 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Saudi Arabia key country dynamics
  • Fig. 85 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 UAE key country dynamics
  • Fig. 87 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Kuwait key country dynamics
  • Fig. 89 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Market share of key market players- Skin cancer diagnostics market